Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients

Current role and future perspectives

Lucia Del Mastro, Alessia Levaggi, Sara Giraudi, Paolo Pronzato

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Luteinising hormone releasing hormone agonists (LH-RHa) induce ovarian suppression in premenopausal women that is usually reversible on cessation of therapy. They act by binding to pituitary LH-RH receptors, resulting in down regulation of receptors and subsequent suppression of luteinising hormone and estradiol. LH-RHa are effective in the treatment of advanced breast cancer in premenopausal women but their role as adjuvant treatment of early breast cancer is still controversial. Approximately 60% of tumors in premenopausal women are hormone sensitive and these patients are candidates for hormonal treatment. Tamoxifen for 5. years is considered the standard endocrine therapy for all premenopausal women with hormone sensitive breast cancer. There is no definitive evidence of additional benefit associated with the use of LH-RHa administered as an alternative or in addition to tamoxifene. In this review we discuss available data on the role of LH-RHa alone or in combination with tamoxifen; on the role of LH-RHa in combination with aromatase inhibitors; and on the potential role of LH-RHa as a strategy to preserve ovarian function during adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)208-211
Number of pages4
JournalCancer Treatment Reviews
Volume37
Issue number3
DOIs
Publication statusPublished - May 2011

Fingerprint

Gonadotropin-Releasing Hormone
Breast Neoplasms
Tamoxifen
Hormones
Therapeutics
LH Receptors
Aromatase Inhibitors
Adjuvant Chemotherapy
Luteinizing Hormone
Estradiol
Down-Regulation
Neoplasms

Keywords

  • Adjuvant therapy
  • Early breast cancer
  • Endocrine therapy
  • Infertility
  • LH-RH agonists
  • Ovarian ablation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{b79e341e58974d03a399dc4c6e995b1f,
title = "Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: Current role and future perspectives",
abstract = "Luteinising hormone releasing hormone agonists (LH-RHa) induce ovarian suppression in premenopausal women that is usually reversible on cessation of therapy. They act by binding to pituitary LH-RH receptors, resulting in down regulation of receptors and subsequent suppression of luteinising hormone and estradiol. LH-RHa are effective in the treatment of advanced breast cancer in premenopausal women but their role as adjuvant treatment of early breast cancer is still controversial. Approximately 60{\%} of tumors in premenopausal women are hormone sensitive and these patients are candidates for hormonal treatment. Tamoxifen for 5. years is considered the standard endocrine therapy for all premenopausal women with hormone sensitive breast cancer. There is no definitive evidence of additional benefit associated with the use of LH-RHa administered as an alternative or in addition to tamoxifene. In this review we discuss available data on the role of LH-RHa alone or in combination with tamoxifen; on the role of LH-RHa in combination with aromatase inhibitors; and on the potential role of LH-RHa as a strategy to preserve ovarian function during adjuvant chemotherapy.",
keywords = "Adjuvant therapy, Early breast cancer, Endocrine therapy, Infertility, LH-RH agonists, Ovarian ablation",
author = "Mastro, {Lucia Del} and Alessia Levaggi and Sara Giraudi and Paolo Pronzato",
year = "2011",
month = "5",
doi = "10.1016/j.ctrv.2010.07.007",
language = "English",
volume = "37",
pages = "208--211",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients

T2 - Current role and future perspectives

AU - Mastro, Lucia Del

AU - Levaggi, Alessia

AU - Giraudi, Sara

AU - Pronzato, Paolo

PY - 2011/5

Y1 - 2011/5

N2 - Luteinising hormone releasing hormone agonists (LH-RHa) induce ovarian suppression in premenopausal women that is usually reversible on cessation of therapy. They act by binding to pituitary LH-RH receptors, resulting in down regulation of receptors and subsequent suppression of luteinising hormone and estradiol. LH-RHa are effective in the treatment of advanced breast cancer in premenopausal women but their role as adjuvant treatment of early breast cancer is still controversial. Approximately 60% of tumors in premenopausal women are hormone sensitive and these patients are candidates for hormonal treatment. Tamoxifen for 5. years is considered the standard endocrine therapy for all premenopausal women with hormone sensitive breast cancer. There is no definitive evidence of additional benefit associated with the use of LH-RHa administered as an alternative or in addition to tamoxifene. In this review we discuss available data on the role of LH-RHa alone or in combination with tamoxifen; on the role of LH-RHa in combination with aromatase inhibitors; and on the potential role of LH-RHa as a strategy to preserve ovarian function during adjuvant chemotherapy.

AB - Luteinising hormone releasing hormone agonists (LH-RHa) induce ovarian suppression in premenopausal women that is usually reversible on cessation of therapy. They act by binding to pituitary LH-RH receptors, resulting in down regulation of receptors and subsequent suppression of luteinising hormone and estradiol. LH-RHa are effective in the treatment of advanced breast cancer in premenopausal women but their role as adjuvant treatment of early breast cancer is still controversial. Approximately 60% of tumors in premenopausal women are hormone sensitive and these patients are candidates for hormonal treatment. Tamoxifen for 5. years is considered the standard endocrine therapy for all premenopausal women with hormone sensitive breast cancer. There is no definitive evidence of additional benefit associated with the use of LH-RHa administered as an alternative or in addition to tamoxifene. In this review we discuss available data on the role of LH-RHa alone or in combination with tamoxifen; on the role of LH-RHa in combination with aromatase inhibitors; and on the potential role of LH-RHa as a strategy to preserve ovarian function during adjuvant chemotherapy.

KW - Adjuvant therapy

KW - Early breast cancer

KW - Endocrine therapy

KW - Infertility

KW - LH-RH agonists

KW - Ovarian ablation

UR - http://www.scopus.com/inward/record.url?scp=79952004670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952004670&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2010.07.007

DO - 10.1016/j.ctrv.2010.07.007

M3 - Article

VL - 37

SP - 208

EP - 211

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 3

ER -